Skip to search formSkip to main contentSkip to account menu

Mopidamol

Known as: 2,2',2",2"'-[[4-(1-Piperidinyl)pyrimido[5,4-d]pyrimidine-2,6-diyl]dinitrilo]tetrakisethanol, 2,2',2",2"'-[(4-Piperidinopyrimido[5,4-d-]pyrimidine-2,6-diyl)dinitrilo]tetraethanol, Mopidamol [Chemical/Ingredient] 
A phosphodiesterase inhibitor which inhibits platelet aggregation. Formerly used as an antineoplastic.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
A derivative of dipyridamole that is a phosphodiesterase inhibitor, with potential antiplatelet activity. Mopidamol inhibits the… 
2000
2000
L'invention concerne un traitement de medecine animale ou veterinaire dirige contre les troubles de la microcirculation lies a la… 
2000
2000
The present invention discloses a method for treating a human or non-human animal body for treating fibrin-dependent… 
1992
1992
Se ha estudiado la peroxidacion lipidica enzimatica y la inducida por radicales libres en pulmon de rata, pulmon humano… 
1989
1989
Between January 1982 and April 1986 a double-blind randomized placebo controlled study of mopidamol, employed as adjunct therapy… 
1984
1984
The effects of 2,2',2",2"'-[(4-piperidinopyrimido[5,4-d]pyrimidine-2,6- diyl)dinitrilo]-tetraethanol (mopidamol, RA-233), a drug…